Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $10.87 USD
Change Today +0.04 / 0.37%
Volume 1.3M
NKTR On Other Exchanges
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

John Nicholson

Chief Financial Officer and Senior Vice President,Nektar Therapeutics
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 1 different industries.

As of Fiscal Year 2014


Mr. John Nicholson has been the Chief Financial Officer and Senior Vice President at Nektar Therapeutics since December 10, 2007. Mr. Nicholson has more than 25 years of experience in the pharmaceutical industry and served as Senior Vice President of Nektar Therapeutics. He served as Senior Vice President of Corporate Development and Business Operations of Nektar Therapeutics since 2007 and also served as its Principal Accounting Officer until April 2008. Prior to Nektar, ...

Read Full Background

Corporate Headquarters*

455 Mission Bay Boulevard South
San Francisco, California 94158

United States

Phone: 415-482-5300
Fax: 415-339-5300

Board Members Memberships*

There is no Board Members Memberships data available.


The University of Toledo

Other Affiliations*

Annual Compensation*

Total Annual Compensation$542,458

Stock Options*

All Other Compensation$12,854
Exercisable Options1,034,226
Exercisable Options Value$7,779,757
Unexercisable Options288,774
Unexercisable Options Value$1,138,498
Total Value of Options$9,186,880
Total Number of Options1,498,000

Total Compensation*

Total Annual Cash Compensation$963,312
Total Short Term Compensation$542,458
Other Long Term Compensation$12,854
Total Calculated Compensation$3,305,495
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NKTR:US $10.87 USD +0.04


Michael W. Aguiar Chief Executive Officer, President and Director
Theravance Inc.
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
Peter S. Greenleaf Chief Executive Officer and Director
Sucampo Pharmaceuticals, Inc.
Daniel J. Abdun-Nabi Chief Executive Officer, President, Director, Member of Strategic Operations Committee and Member of Pricing Committee
Emergent BioSolutions, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEKTAR THERAPEUTICS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at